Search Results - chimeric+antigen+receptors+(cars)

2 Results Sort By:
Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers
Abstract: Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic.  Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR.  Thus,...
Published: 4/8/2024   |   Inventor(s): Rimas Orentas, Nirali Shah, Ira Pastan, Crystal Mackall, Dimiter Dimitrov
Keywords(s): Acute Lymphoblastic Leukemia, adoptive cell therapy, ALL, B-CELL, CD22, Chimeric antigen receptors (CARs), Chronic lymphocytic leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Immunotherapy, pediatric
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics
IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer
Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer and third leading cause of cancer-related morbidity. Standard treatment for HCC is not suitable for a large proportion of liver cancer patients. Part of this is because less than a quarter of HCC patients are surgical candidates...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Aarti Kolluri, Nan Li
Keywords(s): ANTIBODY, cancer therapeutic, Chimeric antigen receptors (CARs), Glypican-3 (GPC3), Hepatocellular Carcinoma (HCC), HO, IgG4, Liver cancer, Macrophage, NANOBODY, Natural Killer (NK) Cell, T cell, therapeutic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics